ADENOVIRUS TYPE 4 AND TYPE 7 VACCINE, LIVE, ORAL, ENTERIC COATED TABLETS FOR ORAL ADMINISTRATION

The Defense Logistics Agency - Troop Support Medical Supply Chain (DLA-Troop Support) is seeking sources capable of providing the Adenovirus Vaccine. The vaccine shall be live, bivalent, enteric-coated tablets, intended for active immunization for the prevention of respiratory infections caused by the Adenovirus types 4 and 7, suitable for oral administration only. A package (PG) consists of two (2) bottles - one (1) bottle of 100 tablets each of Adenovirus Type 4 and one (1) bottle of 100 tablets each of Adenovirus Type 7. Additionally, one (1) dose shall constitute two (2) tablets - one (1) tablet each of Adenovirus Type 4 and Adenovirus Type 7, or 100 doses per PG. Product shall be FDA approved.

DLA-Troop Support is contemplating awarding an Indefinite Delivery-Indefinite Quantity (IDIQ) contract for the Adenovirus Vaccine with a one-year base period and four (4) one-year option periods. The estimated annual quantity to be ordered is 2,000 Packages (200,000 doses/ 400,000 tablets). The anticipated annual guaranteed minimum purchase quantity is estimated to be 1,500 PG (150,000 doses/300,000 tablets), and the anticipated annual maximum is estimated to be 2,300 PG (230,000 doses/460,000 tablets). The quantities indicated above are estimates only. The quantity may increase or decrease considerably as the requirements are subject to change as the Services requirements change.

The successful offeror shall have Federal Drug Administration (FDA) approval to supply the requisite Adenovirus vaccine prior to contract award. Ordered quantities shall be delivered to various military activities throughout the United States. Delivery is scheduled on a monthly basis to these activities. First deliveries shall begin 3-6 months after contract award, or best available delivery negotiated between the contractor and the government.

THERE IS NO SOLICITATION AT THIS TIME. This is a request for information (RFI) and does not commit the U.S. Government to issue a solicitation, make an award, or pay any costs associated with responding to this RFI. Submission of any information in response to this RFI is purely voluntary. All submitted information shall remain with the U.S. Government and will not be returned.

If your firm currently manufactures or distributes the Adenovirus vaccine, please provide information with respect to the following:

1. Place of Manufacture
2. Estimated Annual Capacity
3. FDA Registration information
4. Product Name and description including description of any special features
5. Current unit sales price
6. Estimated inventory level and storage requirements
7. Delivery days for this item and earliest product available time
8. Capacity for surge and sustainment requirement
9. Country of origin for API
10. Do you have any authorized distributor for this item in the U.S.? If so, please provide the name of the authorized distributor(s).

*** NEW PRODUCTS UNDER DEVELOPMENT***

For products under development, describe the current stage of development and whether the product has undergone independent laboratory testing or FDA testing/trials etc. Firms and organizations that currently develop or manufacture the Adenovirus vaccine or that have technologies, pharmaceuticals, or manufacturing capabilities under development are invited to submit information to DLA Troop Support.

Data obtained from this Request For Information (RFI) will be used by DLA Troop Support in making recommendations and decisions on the development of an appropriate planning and procurement strategy for the Adenovirus. All information submitted shall remain with the U.S. Government and will not be returned. It will be kept confidential as allowed by relevant Federal law and will be eligible for additional special protections under the conditions of the Protected Critical Infrastructure Information (PCII) Program outlined in the Critical Infrastructure Information Act of 2002.

Your response to this RFI may be submitted electronically in PDF format and emailed to contracting officer Yu Chen, yu.chen@dla.mil